Chapter title |
Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
|
---|---|
Chapter number | 35 |
Book title |
Cancer Epigenetics
|
Published in |
Methods in molecular biology, January 2015
|
DOI | 10.1007/978-1-4939-1804-1_35 |
Pubmed ID | |
Book ISBNs |
978-1-4939-1803-4, 978-1-4939-1804-1
|
Authors |
Sharad K Verma, Sharad K. Verma, Verma, Sharad K. |
Abstract |
Epigenetics investigates heritable changes in gene transcription that do not involve a change in DNA sequence, and an increased understanding in the role of epigenetic misregulation as a key contributor to cancer has triggered the development of epigenetic targeted cancer therapies. Among these include efforts around a class of enzymes known as histone methyltransferases (HMTs). The level of interest in the development of HMT inhibitors as a class of anticancer agents has significantly grown beyond academic settings, and in the last 5 years whole research groups from biotech and big pharma have been dedicated to this area. There are now multiple reports describing small-molecule HMT inhibitors, including chemical probes and drug candidates entering the clinic as first-in-class agents. Recent progress in this emerging area is the topic of this chapter. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 17% |
Unknown | 5 | 83% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 2 | 33% |
Researcher | 1 | 17% |
Lecturer | 1 | 17% |
Student > Master | 1 | 17% |
Unknown | 1 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 2 | 33% |
Agricultural and Biological Sciences | 1 | 17% |
Chemistry | 1 | 17% |
Unknown | 2 | 33% |